ROCKVILLE, MD and SHENZHEN, CHINA, September 19, 2024—HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, announced today that it will present at the 8^th Annual MASH Drug Development Summit, taking place from September 24-26, 2024 in Boston, Massachusetts. The presentation will be delivered by Dr. Alexander Liberman, Director, Clinical Science.

“Further Rationales for Holistic Approaches to Treating MASH and Metabolic Diseases”

(Oral Presentation, September 26, 1:45 PM EDT)

· Brief overview of epidemiology and risk factors in MASH and metabolic diseases including the added risks when multiple metabolic diseases are present

· Discuss the preliminary benefits observed in metabolic and hepatic endpoints in Phase 2 studies of berberine ursodeoxycholate (HTD1801)

About HighTide Therapeutics

HighTide Therapeutics, Inc. (2511.HK) is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional multi-targeted therapies with chronic liver and metabolic diseases with significant unmet medical needs. The company is developing multiple clinical assets, including therapy for metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes (T2DM), severe hypertriglyceridemia (SHTG), primary sclerosing cholangitis (PSC). Berberine ursodeoxycholate (HTD1801), the company’s lead drug candidate, received Fast Track designation from the U.S. FDA for both NASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project.

For more information, please visit www.hightidetx.com

Contact: pr@hightidetx.com